Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMA203CD8 GEN2
- Development stage
- Unknown
- Lead developer
- Immatics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IMA203CD8 GEN2 is a second-generation, autologous T-cell receptor (TCR) engineered T-cell therapy developed by Immatics. It is designed to target the PRAME (PReferentially expressed Antigen in MElanoma) antigen, a cancer-testis antigen highly expressed in various solid tumors. Unlike the first-generation IMA203, this GEN2 version involves the co-transduction of T cells with both a PRAME-specific TCR and a CD8αβ co-receptor. This modification is intended to functionalize CD4+ T cells, enabling them to contribute directly to the anti-tumor response alongside CD8+ T cells, thereby enhancing the overall potency and durability of the therapy. It is currently being evaluated in Phase 1 clinical trials for advanced solid tumors, including melanoma, ovarian cancer, and uterine cancer, specifically in patients who are HLA-A*02:01 positive.
- Other names
- IMA203CD8IMA-203CD8IMA 203CD8
02
Targets
PRAME peptide–HLA complex
Beyond the preview
Go deeper on IMA203CD8 GEN2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMA203CD8 GEN2.